Return, now, to the tension this module opened with. This program has spent its core curriculum teaching you that concentration, held with conviction and backed by deep research, is a legitimate (often the correct) response to genuine insight: diversification-for-its-own-sake dilutes your best ideas toward mediocrity, and the investors this program most admires built their results by concentrating hard on what they understood best. A private-wealth client sitting on 77% of their net worth in one listed stock looks, on the surface, exactly like the concentration this program celebrates. It usually is not the same thing, and learning to tell the two apart precisely is the actual skill this section teaches.
How do you tell conviction from concentration risk?
The test is not "how much is concentrated", it is whose analytical conviction the position represents, and what else is correlated with it. A position you built yourself, stock by stock, because your own research convinced you the market was wrong about a specific business, is concentration as an expressed edge: you can articulate why you hold it, you would buy more at today's price if you did not already own it, and if your thesis breaks, you sell, the same discipline this program's own sell-discipline modules teach for any position. A position that arrived as vested employee stock options, an inheritance, or a founder's equity that simply never got sold is categorically different, for a reason that has nothing to do with anyone's investment skill: it is very often correlated with the client's human capital, because the same company that pays their salary is the company whose stock dominates their balance sheet. If that employer has a bad year, the client can lose their job and watch their portfolio fall at the same time, from the same cause, a correlation an outside investor holding the identical stock simply does not carry, because an outside investor's paycheck does not depend on that company at all. This is precisely why a private-wealth adviser's job, here, is not "talk the client out of conviction", it is to ask, honestly, whether this position is conviction, or whether it is an accident of employment wearing conviction's clothes, and to manage the latter as the concentrated risk it is, regardless of how good the underlying business might be.
Advertisement
Why stage the sale of a concentrated position?
Once concentration is diagnosed as a risk-management problem rather than a conviction position, the toolkit is practical, and the tax mechanics differ sharply by market. A staged sale (trimming a position over several tranches rather than all at once) is the default first tool in both markets, but for very different reasons, and conflating the two is a common advisory mistake. In the United States, staging a sale across tax years genuinely matters, because the US system is meaningfully progressive at the margin: spreading realized gains across years can keep long-term gains inside the 15% bracket rather than spilling into the 20% bracket, and can keep modified adjusted gross income under the 3.8% Net Investment Income Tax threshold in a given year: real, bracket-management reasons to stage. In India, by contrast, listed-equity long-term capital gains are taxed at a flat 12.5% rate above a modest annual exemption (₹1,25,000, current since the July 2024 Budget. Section 112A, check against the current Finance Act) with no progressive bracket to manage. Worked Example 5 computes this directly and shows that staging a large Indian ESOP position across five years, versus selling it all in one year, saves almost nothing in tax (only the trivial extra exemption used in the additional years), because the rate itself does not change with the size of the gain. The real reasons to stage a large Indian concentrated position are different ones entirely: managing market-impact and execution on a large block, respecting SEBI's insider-trading trading-window and pre-clearance requirements if the holder is a "designated person" (the analogue to a US Rule 10b5-1 pre-arranged trading plan for a corporate insider). ES1.03 section 10 defines both regimes: what a designated person is, when the window closes and reopens around a results announcement, what pre-clearance actually requires, and how a pre-arranged plan establishes the affirmative defence, and giving the client time to adjust behaviorally to a shrinking position rather than dealing with it as a single, jarring decision. Naming the right reason for staging, market by market, is itself part of giving competent advice, overselling the exemption's importance on a crore-scale Indian position is a subtler version of the same mistake as ignoring the US bracket-management benefit entirely.
Beyond staging, three further tools round out the kit, each referenced rather than re-derived here. A zero-cost collar, simultaneously buying a protective put below the current price and selling a covered call above it, structured so the premiums roughly offset, creates a floor and a cap on a tranche of the position without an immediate sale (Worked Example 5 shows the payoff bookkeeping on a sample tranche); the actual strike selection, pricing, and Greeks-level hedge management is DV1.02–DV1.03's territory, not re-derived here. Donating appreciated stock to a qualified charity is, in the US, a well-established double benefit, the donor generally avoids the embedded capital gain entirely on the donated shares while also claiming a deduction at fair market value, subject to the usual itemized-deduction limits; India's parallel is a Section 80G deduction for a donation to an eligible institution, combined with the Income Tax Act's general treatment of a genuine gift transfer as outside the scope of a taxable "transfer", worth flagging to a client as a lever, though the precise scope and any conditions attached to a share-transfer donation in India are exactly the kind of statutory detail to confirm with a tax professional before executing, not to assert with false precision here. And for a client whose concentration sits inside an illiquid, pre-exit private company rather than a listed stock (a founder or very early employee before any liquidity event) the position is not yet sellable at all in the ordinary sense, and M3.10 §4.7's framing of founder equity as a call option on the firm's assets is the right lens until a real exit (E11.02's territory) creates something to actually unwind.
Diversifying without selling: four more tools
Paul Ortega (synthetic), 58, sits on the board of a listed US software company and holds 400,000 of its shares at $50, bought at $5. Selling would realise $18 million of gain. He wants protection and some cash without that tax bill arriving now. Four tools meet different parts of the wish.
A collar buys a put below the price and sells a call above it, setting a floor and a cap for the options' term while the call's premium pays for some or all of the put. For a director the binding limit is the company's insider-trading policy. US listed companies must disclose whether they let directors and employees hedge company stock, and many forbid it. Where hedging is allowed it usually needs pre-clearance and must avoid the closed windows around results. In India the 2015 insider-trading regulations dropped the older outright ban on derivatives, but a designated person still cannot trade in a closed window, needs pre-clearance above the code's threshold and may not reverse a trade within six months. Several large listed companies ban derivatives in their own codes.
The collar also makes the shares better collateral. A lender that advances half the value of an unhedged stock will lend a larger share against the put's floor, because the put removes the fall it feared. A collared loan raises cash without a sale.
A prepaid variable forward pays cash now, typically 75% to 85% of the shares' value, against a promise to deliver shares at the end of a term of three to five years. The number of shares delivered falls as the price rises, so the holder keeps a band of the upside. Under a 2003 US revenue ruling, a forward that leaves the holder free to settle in cash or other shares is not a sale until it settles, so the tax waits until then. The IRS treats one whose shares are lent to the dealer as a sale today.
An exchange fund is a partnership that pools appreciated shares from many holders. Contributing shares to a partnership is not taxed, provided the fund keeps at least 20% of its assets outside securities, usually in real estate. After seven years a partner may leave with a basket of the pool's shares, still on the old cost basis, so tax falls due only when those shares are sold. The price is a seven-year lock-up and the votes on the shares contributed.
A completion portfolio leaves the shares where they are. Other assets are invested to offset the holding's sector and style tilts, so that total wealth behaves more like a broad index. Nothing is sold and no tax arises, but it needs enough other wealth to do the offsetting.
Neither the exchange fund nor the prepaid forward is a standard product for an Indian holder. The Indian toolkit comes down to a staged sale or a loan against shares, plus a collar where the stock has listed options and the insider code allows one.